Drozdz Włodzimierz, Sarwa Aneta, Labza Henryk
II Katedra Chirurgii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Przegl Lek. 2006;63(5):271-7.
Ischemic preconditioning (IP), has emerged as a powerful experimental method of ameliorating ischemic-reperfusion injury in a variety of organs. Clinical trials using IP have been successfully carried out. They support the existence of IP induced cyto-protection in humans as well. IP induced "ischemia tolerance" and "reperfusion tolerance" mechanisms are presented. The new, recently discovered modifications of IP "remote preconditioning" and "postconditioning" and their possible clinical applications in the ischemia of human: heart, liver, lung, brain, kidney and skeletal muscles are discussed.
缺血预处理（IP）已成为一种在多种器官中减轻缺血再灌注损伤的有力实验方法。使用IP的临床试验已成功开展。这些试验也支持IP诱导的细胞保护在人体中存在。文中介绍了IP诱导的“缺血耐受”和“再灌注耐受”机制。还讨论了IP的新的、最近发现的变体“远程预处理”和“后处理”及其在人类心脏、肝脏、肺、脑、肾脏和骨骼肌缺血中的可能临床应用。
